Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Clinical use of cyclooxygenase inhibitors impairs vitamin B-6 metabolism.

Chang HY, Tang FY, Chen DY, Chih HM, Huang ST, Cheng HD, Lan JL, Chiang EP.

Am J Clin Nutr. 2013 Dec;98(6):1440-9. doi: 10.3945/ajcn.113.064477. Epub 2013 Oct 23.

2.

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.

Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, L├╝scher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE; PRECISION Investigators.

Am Heart J. 2009 Apr;157(4):606-12. doi: 10.1016/j.ahj.2008.12.014. Epub 2009 Feb 25.

PMID:
19332185
3.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
4.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.

Am J Gastroenterol. 2001 Apr;96(4):1019-27.

PMID:
11316141
6.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327
7.

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

Arch Intern Med. 2003 Feb 24;163(4):481-6.

PMID:
12588209
9.

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators.

Am J Med. 2006 Mar;119(3):255-66. Erratum in: Am J Med. 2006 Sep;119(9):801.

PMID:
16490472
10.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
11.

Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.

Daniels S, Robbins J, West CR, Nemeth MA.

Clin Ther. 2009 Jun;31(6):1192-208. doi: 10.1016/j.clinthera.2009.06.003.

PMID:
19695387
12.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
14.

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.

Whelton A, Maurath CJ, Verburg KM, Geis GS.

Am J Ther. 2000 May;7(3):159-75. Review. Erratum in: Am J Ther 2000 Sep;7(5):341.

PMID:
11317165
15.
16.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
17.

Celecoxib for rheumatoid arthritis.

Megeff CE, Strayer SM.

J Fam Pract. 2000 Feb;49(2):108-9. No abstract available.

PMID:
10718683
20.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069

Supplemental Content

Support Center